Date of Award
Master of Science (MS)
Biochemistry and Molecular Biology
Dr. Bilal Bin Hafeez
Dr. Nirakar Sahoo
Dr. Manish Tripathi
Pancreatic cancer (PanCa) is one of the leading causes of cancer-related death in the United States. Currently, PanCa is one of the recalcitrant cancers that has very limited therapeutic options available for its treatment. The current standard care of PanCa is gemcitabine (GEM) alone or in combination with FOLFIRINOX, nab-paclitaxel, erlotinib, or 5-FU PanCa, which often show poor response. Therefore, new treatment strategies are required for the prevention and treatment of cancer. Ribosome biogenesis process is dysregulated in most of the cancer types of results in production of more ribosomes and synthesis of oncoproteins which lead to the induction, progression, and metastasis of cancer. This process in the cancer cells can be controlled by pharmacological inhibitors targeting various components of ribosome biogenesis. BMH-21 is a non-toxic selective inhibitor of RNA Polymerase I that inhibits ribosome biogenesis via binding to GC rich ribosomal DNA (rDNA) resulting inhibition of RNA polymerase I activity. BMH-21 has been shown for its potent anti-cancer effects against solid tumors in preclinical mouse models, but no study exists in the literature to explore its therapeutic efficacy against pancreatic cancer.
Perez, Carlos III, "Targeting Ribosome Biogenesis for Pancreatic Cancer Treatment" (2022). Theses and Dissertations. 938.